Cross-Sector entity
Of the tracked stories, 2 of 2 also mention HMI-115, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 10 original sources each.
2 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention HMI-115, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 10 original sources each. Peking Union Medical College Hospital appears in 2 tracked Cross-Sector stories from March 25, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Peking Union Medical College Hospital. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
